33620 Results

People

  1. Ladanyi
    Ladanyi
  2. Giralt
    Giralt
  3. Motzer
    Motzer
  4. Reuter
    Reuter
  5. Perales
    Perales
  6. Scher
    Scher
  7. Zelenetz
    Zelenetz
  8. Berger
    Berger
  9. Al-Ahmadie
    Al-Ahmadie
  10. O'Reilly
    O'Reilly

Groups

  1. Department of Medicine (15822)
  2. Solid Tumor Oncology Division (9435)
  3. GSK Faculty (7076)
  4. Hematologic Malignancies, Division of (6210)
  5. Center for Hematologic Malignancies (6017)
  6. Survivorship Research (5192)
  7. Department of Pathology and Laboratory Medicine (5172)
  8. Surgery (4871)
  9. Sloan Kettering Institute Faculty (3826)
  10. Sloan Kettering Institute Postdocs (3612)
  1. "Meeting abstract"
Formats
  1. Meeting Abstract (33620)
Groups
  1. Department of Medicine (15822)
  2. Solid Tumor Oncology Division (9435)
  3. GSK Faculty (7076)
  4. Hematologic Malignancies, Division of (6210)
  5. Center for Hematologic Malignancies (6017)
  6. Survivorship Research (5192)

More Groups

People
  1. Marc Ladanyi (641)
  2. Sergio Giralt (632)
  3. Robert Motzer (574)
  4. Victor Reuter (568)
  5. Miguel-Angel Perales (482)
  6. Howard Scher (463)

More People

Years
  1. 2025 (295)
  2. 2024 (1694)
  3. 2023 (1954)
  4. 2022 (2196)
  5. 2021 (1731)
  6. 2020 (1901)

More Years

Publications
  1. Journal of Clinical Oncology (6252)
  2. Blood (3939)
  3. Laboratory Investigation (1846)
  4. Cancer Research (1822)
  5. International Journal of Radiation Oncology, Biology, Physics (1643)
  6. Modern Pathology (1494)

More Publications

Publishers
  1. American Society of Clinical Oncology (6251)
  2. Elsevier Inc. (4694)
  3. American Society of Hematology (3939)
  4. American Association for Cancer Research (3045)
  5. Nature Publishing Group (2151)
  6. Oxford University Press (2096)

More Publishers

Results (33620)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Nivolumab safety profile in Asian and Western patients with chemotherapy-refractory (CTx-R) advanced gastric/gastroesophageal junction (adv G/GEJ) cancer from the ATTRACTION-2 and CheckMate-032 trials
    Meeting Abstract

    Haag, G. M.; Chen, L. T.; Kang, Y. K.; Satoh, T.; Kato, K.; Chung, H. C.; Kang, W. K.; Chao, Y.; Chen, J. S.; Ott, P. A.; more...
    Oncology Research and Treatment (2018)

    Fulltext@MSK | Save
  • Sonic hedgehog methylation subgrouping is a prognostic factor for young children with nodular desmoplastic medulloblastoma: A report of Children's Oncology Group study ACNS1221
    Meeting Abstract

    Lafay-Cousin, L.; Robinson, G.; Rudneva, V.; Northcott, P.; Billups, C.; Onar-Thomas, A.; Hawkins, C.; Eberhart, C.; Horbinski, C.; Heier, L.; more...
    Pediatric Blood and Cancer (2018)

    Fulltext@MSK | Save
  • Quantification of drug synergism in vivo exemplified for the combination of Taxotere and T607 against colon carcinoma HCT-116 xenograft tumors in nude mice
    Meeting Abstract

    Ulrich-Merzenich, G.; Fu, J.; Chou, J. H.; Chou, T. C.
    Oncology Research and Treatment (2018)

    Fulltext@MSK | Save
  • CheckMate 227: Nivolumab (Nivo) + ipilimumab (Ipi) vs platinum-doublet chemotherapy (Chemo) as first-line treatment for advanced non-small cell lung cancer (NSCLC) with high tumor mutational burden (TMB)
    Meeting Abstract

    Reck, M.; Hellmann, M. D.; Paz-Ares Rodriguez, L.; Ramalingam, S. S.; Brahmer, J.; O'Byrne, K. J.; Bhagavatheeswaran, P.; Nathan, F.; Borghaei, H.
    Oncology Research and Treatment (2018)

    Fulltext@MSK | Save
  • Outcomes in patients (pts) who had received sorafenib (S) as the only prior systemic therapy in the phase 3 CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma (HCC)
    Meeting Abstract

    Venerito, M.; Kelley, R. K.; Ryoo, B. Y.; Merle, P.; Park, J. W.; Bolondi, L.; Chan, S. L.; Lim, H. Y.; Baron, A.; Parnis, F.; more...
    Oncology Research and Treatment (2018)

    Fulltext@MSK | Save
  • Cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC) who have received prior sorafenib: results from the randomized phase 3 CELESTIAL trial
    Meeting Abstract

    Waidmann, O.; Abou-Alfa, G. K.; Meyer, T.; Cheng, A. L.; El-Khoueiry, A. B.; Rimassa, L.; Ryoo, B. Y.; Cicin, I.; Merle, P.; Chen, Y. H.; more...
    Oncology Research and Treatment (2018)

    Fulltext@MSK | Save
  • Outcomes based on age in the phase 3 CELESTIAL trial of cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC)
    Meeting Abstract

    Venerito, M.; Rimassa, L.; Cicin, I.; Blanc, J. F.; Klümpen, H. J.; Zagonel, V.; Tran, A.; Kim, S.; Lin, Z. Z.; Tam, V. C.; more...
    Oncology Research and Treatment (2018)

    Fulltext@MSK | Save
  • Clinicogenetic risk factors in patients receiving autologous stem-cell transplantation after frontline R-CHOP for advanced follicular lymphoma: An analysis from the GLSG2000 trial
    Meeting Abstract

    Alig, S.; Pastore, A.; Jurinovic, V.; Bararia, D.; Häbe, S.; Passerini, V.; Keay, W.; Hellmuth, J.; Rosenwald, A.; Klapper, W.; more...
    Oncology Research and Treatment (2018)

    Fulltext@MSK | Save
  • Ibrutinib/rituximab versus placebo/rituximab in Waldenström's macroglobulinemia (WM): Results of a randomized phase 3 trial
    Meeting Abstract

    Buske, C.; Tedeschi, A.; Trotman, J.; García-Sanz, R.; MacDonald, D.; Leblond, V.; Mahe, B.; Herbaux, C.; Tam, C. S.; Palomba, M. L.; more...
    Oncology Research and Treatment (2018)

    Fulltext@MSK | Save
  • Clinical outcomes by nephrectomy status in METEOR, a randomized phase 3 trial of cabozantinib (cabo) vs everolimus (eve) in patients (pts) with advanced renal cell carcinoma (RCC)
    Meeting Abstract

    Schmidinger, M.; Tannir, N. M.; Powles, T.; Escudier, B. J.; Donskov, F.; Grünwald, V.; Sternberg, C. N.; Schoffski, P.; Szczylik, C.; Peltola, K. J.; more...
    Oncology Research and Treatment (2018)

    Fulltext@MSK | Save